-
EP1734997
European procedure
Extract from the Register of European Patents
EP About this file: EP1734997
| EP1734997 - NATALIZUMAB FOR USE IN TREATING DISEASES NEEDING STEROID TREATMENT [Right-click to bookmark this link] | |||
| Former [2006/52] | STEROID SPARING AGENTS AND METHODS OF USING SAME | ||
| [2015/04] | Status | Patent revoked Status updated on 18.10.2024 Database last updated on 03.04.2025 | |
| Former | The patent has been granted Status updated on 25.07.2017 | Most recent event Tooltip | 18.10.2024 | Revocation of patent | published on 20.11.2024 [2024/47] | Applicant(s) | For all designated states Biogen MA Inc. 225 Binney Street Cambridge, MA 02142 / US | [2017/44] |
| Former [2016/10] | For all designated states Biogen MA Inc. 250 Binney Street Cambridge, MA 02142 / US | ||
| Former [2013/45] | For all designated states Biogen Idec MA Inc. 14 Cambridge Center Cambridge, Massachusetts 02142 / US | ||
| Former [2006/52] | For all designated states ELAN PHARMACEUTICALS, INC. 800 Gateway Boulevard South San Francisco, CA 94080 / US | Inventor(s) | 01 /
LIEBERBURG, Ivan 85 Hillcrest Road Berkeley, California 94705 / US | [2006/52] | Representative(s) | Pohlman, Sandra M. df-mp Patentanwälte Rechtsanwälte PartG mbB Theatinerstraße 16 80333 München / DE | [N/P] |
| Former [2015/36] | Schüssler, Andrea, et al Kanzlei Huber & Schüssler Truderinger Strasse 246 81825 München / DE | ||
| Former [2006/52] | Schüssler, Andrea, et al Kanzlei Huber & Schüssler Truderinger Strasse 246 81825 München / DE | Application number, filing date | 05768245.2 | 30.03.2005 | [2006/52] | WO2005US10848 | Priority number, date | US20040558120P | 01.04.2004 Original published format: US 558120 P | [2006/52] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2005099776 | Date: | 27.10.2005 | Language: | EN | [2005/43] | Type: | A2 Application without search report | No.: | EP1734997 | Date: | 27.12.2006 | Language: | EN | The application published by WIPO in one of the EPO official languages on 27.10.2005 takes the place of the publication of the European patent application. | [2006/52] | Type: | B1 Patent specification | No.: | EP1734997 | Date: | 02.09.2015 | Language: | EN | [2015/36] | Search report(s) | International search report - published on: | EP | 18.05.2006 | Classification | IPC: | A61K39/395, A61P1/00, A61P11/06, A61P37/00 | [2015/04] | CPC: |
C07K16/2842 (EP,US);
A61K31/505 (EP,US);
A61K31/52 (EP,US);
A61K31/635 (EP,US);
A61P1/00 (EP);
A61P1/04 (EP);
A61P11/00 (EP);
A61P11/06 (EP);
A61P19/02 (EP);
A61P25/00 (EP);
A61P29/00 (EP);
A61P37/00 (EP);
A61P37/06 (EP);
C07K16/2839 (EP,US);
C07K16/468 (US);
A61K2039/505 (EP,US);
C07K2317/21 (US);
C07K2317/24 (EP,US);
|
| Former IPC [2006/52] | A61K39/395 | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR [2015/36] |
| Former [2006/52] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR | Title | German: | NATALIZUMAB ZUR VERWENDUNG BEI DER BEHANDLUNG VON KRANKHEITEN MIT KORTIKOSTEROID-THERAPIE | [2015/04] | English: | NATALIZUMAB FOR USE IN TREATING DISEASES NEEDING STEROID TREATMENT | [2015/04] | French: | NATALIZUMAB ET SON UTILISATION DANS LE TRAITEMENT DES MALADIES NECESSITANTS DES CORTICOSTEROIDS. | [2015/04] |
| Former [2006/52] | STEROID-SPARENDE MITTEL UND VERFAHREN ZU DEREN VERWENDUNG | ||
| Former [2006/52] | STEROID SPARING AGENTS AND METHODS OF USING SAME | ||
| Former [2006/52] | AGENTS LIMITANT LES EFFETS STEROIDIENS ET METHODES D'UTILISATION ASSOCIEES | Entry into regional phase | 06.10.2006 | National basic fee paid | 06.10.2006 | Designation fee(s) paid | 06.10.2006 | Examination fee paid | Examination procedure | 06.10.2006 | Examination requested [2006/52] | 15.12.2006 | Amendment by applicant (claims and/or description) | 27.04.2009 | Despatch of a communication from the examining division (Time limit: M06) | 06.11.2009 | Reply to a communication from the examining division | 26.04.2013 | Despatch of a communication from the examining division (Time limit: M06) | 05.11.2013 | Reply to a communication from the examining division | 02.12.2013 | Despatch of a communication from the examining division (Time limit: M04) | 28.03.2014 | Reply to a communication from the examining division | 10.03.2015 | Communication of intention to grant the patent | 10.07.2015 | Fee for grant paid | 10.07.2015 | Fee for publishing/printing paid | 10.07.2015 | Receipt of the translation of the claim(s) | Divisional application(s) | EP15002245.7 Application refused : 06.05.2016 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 27.04.2009 | Opposition(s) | Opponent(s) | 01
01.06.2016
ADMISSIBLE Pharmaceutical Works Polpharma SA Pelplinska 19 83-200 Starogard Gdanski / PL Opponent's representative Wichmann, Hendrik Wuesthoff & Wuesthoff Patentanwälte und Rechtsanwalt PartG mbB Schweigerstraße 2 81541 München / DE | [N/P] |
| Former [2016/27] | |||
| Opponent(s) | 01
01.06.2016
ADMISSIBLE Pharmaceutical Works Polpharma SA Pelplinska 19 83-200 Starogard Gdanski / PL Opponent's representative Wichmann, Hendrik Wuesthoff & Wuesthoff Patentanwälte PartG mbB Schweigerstraße 2 81541 München / DE | 07.07.2016 | Invitation to proprietor to file observations on the notice of opposition | 15.11.2016 | Reply of patent proprietor to notice(s) of opposition | 03.07.2017 | Date of oral proceedings | 26.07.2017 | Despatch of minutes of oral proceedings | 21.06.2022 | Date of oral proceedings | 28.07.2022 | Despatch of minutes of oral proceedings | 28.07.2022 | Despatch of communication that the patent will be revoked | 07.10.2024 | Legal effect of revocation of patent [2024/47] | Appeal following opposition | 05.10.2022 | Appeal received No. T2248/22 | 05.10.2022 | Payment of appeal fee | 01.12.2022 | Statement of grounds filed | 07.10.2024 | Result of appeal procedure: appeal of the proprietor withdrawn | 29.09.2017 | Appeal received No. T2232/17 | 29.09.2017 | Payment of appeal fee | 04.12.2017 | Statement of grounds filed | 24.02.2021 | Result of appeal procedure: continuation of opposition procedure | 01.07.2021 | Despatch of the decision of the Board of Appeal | Fees paid | Renewal fee | 14.03.2007 | Renewal fee patent year 03 | 14.03.2008 | Renewal fee patent year 04 | 13.03.2009 | Renewal fee patent year 05 | 15.03.2010 | Renewal fee patent year 06 | 15.03.2011 | Renewal fee patent year 07 | 14.03.2012 | Renewal fee patent year 08 | 11.03.2013 | Renewal fee patent year 09 | 12.03.2014 | Renewal fee patent year 10 | 27.03.2015 | Renewal fee patent year 11 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | deleted | [2023/09] | Cited in | International search | [X]WO02070007 (MEDIMMUNE INC [US]) [X] 1-4,13,14* the whole document *; | [X]WO03072040 (ELAN PHARM INC [US], et al) [X] 1-83 * the whole document *; | [X]US2004009169 (TAYLOR JULIE [US], et al) [X] 1-83 * the whole document *; | [XY] - SORBERA L A ET AL, "Natalizumab. Treatment of IBD, treatment of multiple sclerosis: AN100226, AntegrenTM", DRUGS OF THE FUTURE, (200009), vol. 25, no. 9, ISSN 0377-8282, pages 917 - 921, XP002352328 [X] 1-20,28-31,72-76 * the whole document * [Y] 21-27,32-38,43-49,54-60,65-71,77-83 | [X] - NEPOM G T, "Therapy of autoimmune diseases: clinical trials and new biologics", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, (20021201), vol. 14, no. 6, ISSN 0952-7915, pages 812 - 815, XP004390323 [X] 1-24,27,32-35,37,39-46,48,54-57,59,65-68,70,72-80,82 * the whole document * DOI: http://dx.doi.org/10.1016/S0952-7915(02)00397-7 | [PX] - FOX R J ET AL, "New directions in MS therapeutics: vehicles of hope", TRENDS IN IMMUNOLOGY, ELSEVIER, RAHWAY, NJ, US, (200412), vol. 25, no. 12, ISSN 1471-4906, pages 632 - 636, XP004628797 [PX] 1-14,21-28,43-49,54-60,65-71,77-83 * table 1 * DOI: http://dx.doi.org/10.1016/j.it.2004.09.012 | [XY] - ULBRICH H ET AL, "Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, (200312), vol. 24, no. 12, ISSN 0165-6147, pages 640 - 647, XP004476617 [X] 1-20,28-31,39-42,50-53,61-64,72-76 * the whole document * [Y] 21-27,32-38,43-49,54-60,65-71,77-83 DOI: http://dx.doi.org/10.1016/j.tips.2003.10.004 | by applicant | US3773919 | EP0133988 | WO9007861 | EP0404097 | WO9222653 | WO9311161 | US5224539 | US5530101 | US5585089 | US5693761 | US5840299 | US6033665 | US6054297 | WO02070007 | WO03072040 | US2004009169 | - SPRINGER ET AL., CELL, (1994), vol. 76, pages 301 - 14 | - BUTCHER ET AL., SCIENCE, (1996), vol. 272, pages 60 - 6 | - DAMLE ET AL., J. IMMUNOL., (1993), vol. 151, pages 2368 - 79 | - KOOPMAN ET AL., J. IMMUNOL., (1994), vol. 152, pages 3760 - 7 | - LEUSSINK ET AL., ACTA NEUROPATHOL., (2002), vol. 103, pages 131 - 136 | - SORBERA ET AL., DRUGS OF THE FUTURE, (2000), vol. 25, no. 9, pages 917 - 921 | - QUEEN ET AL., PROC. NATL ACAD. SCI. USA, (1989), vol. 86, pages 10029 - 33 | - PLUCKTHUN, The Pharmacology of Monoclonal Antibodies, SPRINGER-VERLAG, (1994), vol. 113, pages 269 - 315 | - HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 8 | - ZAPATA ET AL., PROTEIN ENG., (1995), vol. 8, no. 10, pages 1057 - 62 | - LANGER ET AL., J. BIOMED. MATER. RES., (1981), vol. 15, pages 167 - 277 | - LANGER, CHEM. TECH., (1982), vol. 12, pages 98 - 105 | - SIDMAN ET AL., BIOPOLYMERS, (1983), vol. 22, pages 547 - 556 | - VINCENT LEE, Peptide and Protein Drug Delivery, MARCEL DEKKER, INC., (1991), pages 247 - 301 | - A. JONES, ADV. DRUG DELIVERY REV., (1993), vol. 10, pages 29 - 90 | Opposition | WO03072040 | WO2004066932 | WO2005099776 | - "Pages 173-177, 227-230, 319-321, 528 - 532", R. Berkow, M.D. et al.,, Merck Manual of Medical Information, Merck & Co.,, (20000900), ISBN 0-671-02726-3, XP055290103 | - "Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody", Drugs in R & D, (20040300), vol. 5, no. 2, pages 102 - 107, XP055290110 | - RUTGEERTS et al., "Subanalyses from a phase 3 study on the evaluation of natalizumab in active Chron`s disease therapy-1 (enact-1) /Oral presentation/", 11th United European Gastroenterology week, Madrid, (20031101), URL: https://www.ueg.eu/home/, XP055290215 | - LÖFBERG, R., "REVIEW ARTICLE: MEDICAL TREATMENT OF MILD TO MODERATELY ACTIVE CROHN'S DISEASE", ALIMENTARY PHARMACOLOGY & THERAPEUTICS,, (20030000), vol. 17, no. Suppl. 2, pages 18 - 22, XP009084498 DOI: http://dx.doi.org/10.1046/j.1365-2036.17.s2.22.x | - MILLER et al., "A CONTROLLED TRIAL OF NATALIZUMAB FOR RELAPSING MULTIPLE SCLEROSIS", The New England Jounral of Medicine, (20030000), vol. 348, pages 15 - 23, XP008076675 DOI: http://dx.doi.org/10.1056/NEJMoa020696 | - GENERINI et al., "Therapy of sondylarthropathy in inflammatory bowel disease", Clinical and Experimental Rheumatology, (20020000), vol. 20, no. Suppl. 28, pages S-88 - S-94, XP055290119 | - SCHÖLMERICH, "Therapeutische Innovationen bei chronisch-entzündlichen Darmerkrankungen durch "biologische Therapie"- Anti-TNF und andere", Der Internist, (20020000), vol. 43, pages 1386 - 1399, XP055290184 | - A. SHAND et al., "Potential therapeutic role for cytokine or adhesion molecule manipulation in Chron`s disease: in the shadow of infliximab?", International Journal of Colorectal Disease, (20030000), vol. 18, no. 1, pages 1 - 11, XP055290189 | - "Spondyloarthropathien", Walter SIEGENTHALER, Hubert E. Blum, Klinische Pathophysiologie 9., völlig neu bearbeitete Auflage, Georg Thieme Verlag, (20060000), page 2pp, iv, 1015, ISBN 978-3-13-449609-3, XP055379799 | - "Intolerance", Stedman, Thomas Lathrop, Stedman's Medical Dictionary 27th Edition, Lippincott Williams & Wilkins, (20000000), page 2pp, 916, XP055379809 |